2004
DOI: 10.1053/j.gastro.2004.05.059
|View full text |Cite
|
Sign up to set email alerts
|

Biliverdin protects the functional integrity of a transplanted syngeneic small bowel

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

4
111
1

Year Published

2007
2007
2020
2020

Publication Types

Select...
8
1

Relationship

3
6

Authors

Journals

citations
Cited by 150 publications
(116 citation statements)
references
References 44 publications
4
111
1
Order By: Relevance
“…These include, severe sepsis [11,41,51], severe malaria [42], ischemia-reperfusion injury [2,14,31], rejection of transplanted organs [8], induction of immunological tolerance [61], autoimmune neuroinflammation [10], restenosis [4,37], myocardial infarction [27] and, as illustrated more recently, type 2 diabetes and obesity [23].…”
Section: Discussionmentioning
confidence: 99%
“…These include, severe sepsis [11,41,51], severe malaria [42], ischemia-reperfusion injury [2,14,31], rejection of transplanted organs [8], induction of immunological tolerance [61], autoimmune neuroinflammation [10], restenosis [4,37], myocardial infarction [27] and, as illustrated more recently, type 2 diabetes and obesity [23].…”
Section: Discussionmentioning
confidence: 99%
“…HO-1 acts on heme and generates three products: biliverdin, carbon monoxide (CO), and Fe 2ϩ . Recent studies of these products have begun to shed light on the mechanisms of HO-1 action as a homeostatic gene (8,(22)(23)(24).…”
Section: Discussionmentioning
confidence: 99%
“…The cellular mechanisms underlie the anti-inflammatory action of CO that lead to inhibition of IL-1, IL-6, TNFα and MIP-1 expression involve the p38 MAPK as well as the JNK signaling pathway and the transcription factor AP-1 Ryter and Otterbein, 2004). Biliverdin has been shown to inhibit the activation of pro-inflammatory transcription factors including NFkB in vitro and in vivo and to decrease inflammatory mediators such as IL-6, TNFα and leukocyte infiltration (Foresti et al, 2004;Nakao et al, 2004;Sarady-Andrews et al, 2005) (Gibbs and Maines, 2007). Induction of HO-1 as well as administration of either CO or biliverdin or both have been shown to lessened tissue damage in various models of injury.…”
Section: Discussionmentioning
confidence: 99%
“…Numerous studies have shown that biliverdin/bilirubin benefit ischemiareperfusion injury and solid-organ transplantation, including chronic rejection, and islet transplantation (Fondevila et al, 2004;Nakao et al, 2004;Yamashita et al, 2004) and suggested it as a novel therapeutic approach to maximize the function and thus the availability of donor organs (Ollinger et al, 2007). In view of the cataractogenic and pressure elevation potential of the currently used glucocorticoids to prevent or treat graft rejection, biliverdin/ bilirubin might constitute an alternative treatment of choice.…”
Section: Discussionmentioning
confidence: 99%